# Zoll Foundation Inc

Private foundation, Chelmsford, Massachusetts. EIN 46-3630772.

Source: the foundation’s own IRS returns, read November 21, 2026, as shown by the Alleviate Index. https://sites.alleviate.org/index/funder/zoll-foundation-inc-463630772

## Gives only to organizations it chooses

Zoll Foundation Inc gives only to organizations it chooses, as stated on its return. It does not accept unsolicited applications.

## What it gave

- Grants paid: $1,297,743 (Year ending March 2025)
- Grants listed: 23 (To organizations, on that return)
- Typical grant: $50,000 (Half fall between $49,675 and $79,953)
- Assets at year end: $27,364,721 (Fair market value)

- March 2025: Grants paid $1,297,743; Grants listed 23
- March 2024: Grants paid $1,561,412; Grants listed 35
- March 2023: Grants paid $1,452,483; Grants listed 33

From the foundation’s Form 990-PF returns for the years ending March 2023 to March 2025.

## What it funds, and where

- Focus, by share of linked grant dollars: Health care 100%
- Where it gave, by number of grants: New York 11, Massachusetts 8, Pennsylvania 5, Minnesota 4, Maryland 4, Illinois 3, California 3, Ohio 2, Virginia 2, District of Columbia 2, Washington 2, New Hampshire 1

## Recent grants to organizations

- MURDOCH CHILDREN'S RESEARCH INSTITUTE (Melbourne, AS): $93,689, year ending March 2025. DR. FERGUSON - RESEARCH FOR LOWER GAS FLOWS DURING RESPIRATORY SUPPORT FOR EXTREMELY PRETERM INFANTS
- GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA): $89,132, year ending March 2025. DR. MORIN - RESEARCH FOR IMPROVING CARDIOPULMONARY RESUSCITATION AND SURVIVAL IN CHILDREN FOLLOWING DROWNING
- THE GENERAL HOSPITAL CORPORATION (Boston, Massachusetts): $85,276, year ending March 2025. DR. MERETO - RESEARCH FOR DELIVERY OF HIGH-DOSE NITRIC OXIDE THROUGH STANDARD EMCO IN A SWINE MODEL TO FIGHT THE WORLDWIDE MULTI-DRUG RESISTANT PATHOGENS EMERGENCY IN CRITICALLY ILL PATIENTS
- BETH ISRAEL DEACONESS MEDICAL CENTER (Boston, Massachusetts): $84,930, year ending March 2025. DR. KRAVITZ - FRESH FROZEN PLASMA TREATMENT FOR GLYCOCALYX DEGRADATION IN SEPSIS
- BETH ISRAEL DEACONESS MEDICAL CENTER (Boston, Massachusetts): $84,231, year ending March 2025. DR. LEE - MONITORING PULMONARY EDEMA IN MECHANICALLY VENTILATED PATIENTS USING WEARABLE STETHOSCOPES
- HEIDELBERG UNIVERSITY HOSPITAL (GM): $82,011, year ending March 2025. DR. KATZENSCHLAGER - DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION IN REFRACTORY VENTRICULAR FIBRILLATION - D.10054715 KATZENSCHLAGER TRIAL, A MULTICENTRIC CLUSTER RANDOMIZED STUDY
- [Dartmouth-Hitchcock Clinic](https://sites.alleviate.org/index/org/dartmouth-hitchcock-clinic-222519596) (Lebanon, New Hampshire): $77,896, year ending March 2025. DR. ERIC ROTHSTEIN - RATE OPTIMIZATION OF THE VEST CPR-T COMPREHENSIVE CARDIAC ARREST RECOVERY SYSTEM UTILIZING A PORCINE VENTRICULAR FIBRILLATION MODEL
- ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (North Chicago, Illinois): $64,872, year ending March 2025. DR. RAZI - SELECTIVE TARGETING OF PERIPHERAL A2-ADRENOCEPTORS WITH A-METHYLNOREPINEPHRINE AS A SUPERIOR ALTERNATIVE TO EPINEPHRINE FOR RESUSCITATION FROM CARDIAC ARREST
- THE MEDICAL UNIVERSITY OF VIENNA AUSTRIA (AU): $60,000, year ending March 2025. DR. HILLEBRAND - THE USE OF EXTRACORPOREAL PHOTOPHERESIS AS IMMUNOMODULATORY THERAPY OF SUBCLINICAL ANTIBODY-MEDICATED REJECTION AFTER LUNG TRANSPLANTATION: A PROSPECTIVE RCT
- MURDOCH CHILDREN'S RESEARCH INSTITUTE (Melbourne, AS): $56,315, year ending March 2025. DR. TURNER - RESEARCH FOR DECODING RHINOVIRUS PNEUMONIA: HOST DEPENDENCIES AND ABERRANT INFLAMMATION IN THE ALVEOLUS
- ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (North Chicago, Illinois): $54,123, year ending March 2025. DR. SAEED - OPTIMIZING THE HEMODYNAMIC MANAGEMENT OF SEPTIC SHOCK BY CONTINUOUS MONITORING OF MICROCIRCULATORY PARAMETERS
- MAYO CLINIC (Rochester, Minnesota): $50,000, year ending March 2025. DR. WIERUSZEWSKI - RESEARCH INTO EVALUATION OF PLASMA RENIN CONCENTRATIONS IN CARDIAC SURGERY
- VIRGINIA COMMONWEALTH UNIVERSITY (Richmond, Virginia): $49,927, year ending March 2025. DR. UZELAC - RESEARCH INTO DEVELOPMENT AND VALIDATION OF INDOCYANINE GREEN FLUORESCENCE IMAGING AND AL-ASSISTED ANALYSIS FOR ASSESSING MYOCARDIAL VIABILITY IN DCD HEARTS DURING COLD STORAGE PRESERVATION
- MURDOCH CHILDREN'S RESEARCH INSTITUTE (Melbourne, AS): $49,911, year ending March 2025. DR. POH - THE MULTIORGAN IMPACT OF ASSISTED VENTILATION TO SUPPORT THE PRETERM LUNG
- FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (Manhasset, New York): $49,816, year ending March 2025. DR. ENDO - A NOVEL MEASURE FOR ASSESSING POST-CARDIAC ARREST SYNDROME SEVERITY BY USING REAL-TIME MEASUREMENTS OF TRANSCUTANEOUS TISSUE CARBON DIOXIDE
- UNIVERSITY OF GONDAR IN ETHIOPIA (ET): $49,710, year ending March 2025. MR. MIHRET - RESEARCH FOR HELPING RESPIRATORY-DISTRESSED NEONATES SURVIVE USING INTEGRATED BUBBLE CONTINUOUS POSITIVE AIRWAY PRESSURE INNOVATIONS WITHIN PRIMARY HEALTH CARE IN ETHIOPIA
- CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio): $49,700, year ending March 2025. DR. RUTLEDGE - RESEARCH INTO TARGETING PROTEOSTASIS TO IMPROVE CARDIAC FUNCTION AFTER ARREST
- VIRGINIA COMMONWEALTH UNIVERSITY (Richmond, Virginia): $49,650, year ending March 2025. DR LIEBRECHT - INVESTIGATING ANTI-INFLAMMATORY MECHANISMS OF A NOVEL PUMP PRIME SOLUTION FOR CPB AND ECMO
- THE GENERAL HOSPITAL CORPORATION (Boston, Massachusetts): $47,500, year ending March 2025. DR. MIRANDA - PERMISSIVE HYPOTENSION AFTER CARDIAC SURGERY: A PILOT RANDOMIZED CLINICAL TRIAL
- THE MEDICAL UNIVERSITY OF VIENNA AUSTRIA (AU): $29,961, year ending March 2025. DR. LINTSCHINGER - NEW DIGITAL TOOLS FOR PREHOSPITAL RESUSCITATION RESEARCH (REBECCA STUDY)
- THE MEDICAL UNIVERSITY OF VIENNA AUSTRIA (AU): $25,217, year ending March 2025. DR. BOLOGHEANU - RESEARCH FOR TREATMENT OUTCOMES IN NEW-ONSET ATRIAL FIBRILLATION IN THE SURGICAL ICU: AN EXPLORATORY STUDY USING HIGH-FIDELITY ECG WAVEFORM DATA
- UNIVERSITY OF THE SUNSHINE COAST (Sippy Downs, AS): $11,306, year ending March 2025. MS. DERMER - MULTIDISCIPLINARY HEALTHCARE PROFESSIONALS' PERCEPTIONS ON THE EFFECTIVENESS OF INNOVATIVE BASIC LIFE SUPPORT EDUCATION SESSIONS
- UNIVERSITY OF ALABAMA AT BIRMINGHAM (Birmingham, Alabama): $2,570, year ending March 2025. DR. COUTE - THE EFFECT OF GLUCOSE -INSULIN-POTASSIUM ON CARDIA ARREST RESUSCITATION IN A SWINE MODEL OF PROLONGED UNTREATED VENTRICULAR FIBRILLATION
- CHILDREN'S NATIONAL HOSPITAL (Nm Washington, District of Columbia): $100,000, year ending March 2024. DR. TON - MECHANISM OF SELECTIVE VULNERABILITY IN THE THALAMIC RETICULAR NUCLEUS AFTER CARDIAC ARREST
- WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY (New York, New York): $85,733, year ending March 2024. DR. OWYANG VA-ECMO-SUPPORT - THE EFFECT OF PEEP ON RV FUNCTION IN ECPR: A PRE-CLINICAL SWINE MODEL

Method and sources: https://sites.alleviate.org/index/method#funders
